Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Ordinary Shares, nominal value 0.05 GBP per share
-
Shares outstanding
-
84,213,667
-
Total 13F shares
-
36,443,868
-
Share change
-
-492,011
-
Total reported value
-
$181,735,244
-
Put/Call ratio
-
0%
-
Price per share
-
$4.99
-
Number of holders
-
38
-
Value change
-
-$2,536,945
-
Number of buys
-
13
-
Number of sells
-
10
Institutional Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) as of Q1 2022
As of 31 Mar 2022,
Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) was held by
38 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,443,868 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., WELLINGTON MANAGEMENT GROUP LLP, PERCEPTIVE ADVISORS LLC, Vivo Capital, LLC, Abingworth LLP, Aisling Capital Management LP, Foresite Capital Management III, LLC, and Samsara BioCapital, LLC.
This page lists
38
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.